CJC 1295 w/DAC
Description
A modified synthetic peptide derivative of Growth Hormone Releasing Hormone (GHRH) featuring Drug Affinity Complex (DAC) technology, researched for its extended systemic half-life and sustained stimulation of growth hormone release.
Available in 2mg–5mg vials, every lot is third-party tested for identity and purity, with certificates of analysis available on request. Vials arrive sealed and sterile, lyophilized for stability, and ship from our U.S. facility in 2–6 days.
For in vitro laboratory research use only. See the Technical Data tab below for the full mechanism and feature summary.
CJC 1295 w/DAC from Wolf Research is a high-purity research-grade compound intended strictly for laboratory research use.
CJC 1295 w/DAC (CJC-1295 with Drug Affinity Complex (DAC:GRF)) is supplied as a research-grade peptide for in vitro study. Synthetic research peptides of this class are widely used in laboratory studies of receptor signaling, tissue biology, and peptide pharmacology.
Every lot of CJC 1295 w/DAC is third-party tested for identity and purity, with certificates of analysis available on request. Supplied in sealed, sterile vials and shipped fast from our U.S. facility.
The products offered herein are intended exclusively for research purposes and must be utilized solely within in vitro environments (e.g., test tubes or laboratory settings) for the purposes of testing and experimentation. All information provided on this website is strictly for educational purposes and does not constitute legal or professional advice. It is imperative to acknowledge that the introduction of these products into humans or animals, in any capacity, is strictly prohibited by applicable laws and regulations. Violation of these regulations may result in legal repercussions. These products are intended solely for use by qualified, licensed professionals with the expertise to handle them safely and responsibly. Furthermore, it is important to note that these products are not classified as drugs, food, or cosmetics under any legal definitions. Any misbranding, misuse, or mislabeling of these products within these categories is expressly prohibited and may lead to further legal consequences. By adhering to these guidelines, you ensure compliance with all regulatory frameworks and contribute to the responsible conduct of scientific research.
Technical Data
| A modified synthetic peptide derivative of Growth Hormone Releasing Hormone (GHRH) featuring Drug Affinity Complex (DAC) technology, researched for its extended systemic half-life and sustained stimulation of growth hormone release. | |
|---|---|
| Key Benefits & Highlights | |
| Drug Affinity Complex (DAC) Technology | Incorporates a maleimidopropionic acid group that bioconjugates to circulating albumin, significantly extending the peptide's active half-life in biological systems. |
| Sustained GHRH Receptor Agonism | Delivers continuous stimulation of growth hormone-releasing hormone receptors, leading to prolonged, elevated baseline levels of growth hormone and IGF-1. |
| Extended Observation Windows | Enable long-term, low-frequency dosing models to evaluate prolonged endocrine signaling and metabolic adaptations. |
| High Chemical Purity | Synthesized to stringent laboratory standards to ensure accurate sequence fidelity and consistent bioactivity across trials. |
| Standardized Research Reagent | Formulated for high reproducibility across in vitro endocrinology assays, receptor kinetic studies, and cellular signaling research. |
| Feature Summary | |
| Product Class | Extended-Release GHRH Analog / Growth Hormone Secretagogue |
| Primary Application | In vitro sustained GHRH signaling & long-term endocrine research |
| Grade | Laboratory / Research Grade Only |